Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313781 · ClinicalTrials.gov registry record · Phase 2
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT00313781: Completed Phase 2 study, sponsored by Pfizer.
NCT00313781 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 204 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00313781, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Primary Outcome
Percentage of participants with PSA best response of either PSA normalization (PN) or partial PSA response (PR) relative to the total number of participants evaluable for response. PN was defined as PSA =\< 0.2 nanogram/milliliter (ng/ml) on 2 successive evaluations at least 3 weeks apart and no imaging or clinical evidence of disease progression. PP was defined as \>= 50% decrease in PSA from baseline on 2 successive evaluations at least 3 weeks apart and no imaging or clinical evidence of dise
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG CP-751,871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT00313781 record still lists
NCT00313781 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00313781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00313781 about?
NCT00313781 is a clinical study titled "Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)". To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
What is the current status of trial NCT00313781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2006-05. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00313781?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), CP-751,871 (DRUG).
Who is sponsoring clinical trial NCT00313781?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00313781's enrollment target sits among peer trials
204 299th of 2000 higher than 1,700 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia